Absci (ABSI) Guggenheim Inaugural Global Healthcare Conference summary

Company evolution and strategic focus

• Originated as a synthetic biology company, pioneering full-length antibody production in E. coli and later pivoted to leverage generative AI for novel therapeutic design around 2020.

• Built a proprietary data generation and AI infrastructure, enabling large-scale antibody screening and iterative model improvement.

• Assembled a world-class drug discovery team, integrating AI, data, and drug development expertise, with leadership experienced in bringing 20 approved drugs to market.

• Transitioned from a service-based model to developing its own pipeline of assets, now advancing internal programs toward clinical trials.

Financial milestones and investor base

• Raised $200 million in its 2021 IPO, followed by an $86 million follow-on offering, both supported by top-tier and generalist investors.

• Navigated 2022 market headwinds by refining strategy and entering high-value partnerships, leading to stock recovery in 2023.

• Investor validation driven by both the platform's capabilities and the quality of proprietary pipeline assets.

• Maintains a strong cash position, with $145 million as of Q2 and a net burn of $16 million, aligning with guidance and development plans.

Platform technology and differentiation

• Platform centers on scalable data generation, active learning AI loops, and integration of drug discovery expertise.

• AI team includes talent from leading tech and academic institutions; partnerships with NVIDIA enable scalable compute.

• Differentiated by the ability to generate high-quality, functional data and demonstrate results, such as de novo antibody design for difficult targets.

• Unique reverse immunology platform identifies novel targets from patient biopsies, validated by both known and novel antibody-target pairs.